Introduction
============

Monoclonal antibody (MoAb) therapy is an accepted treatment modality for cancers, with five MoAb having received FDA approval for solid tumors in adults, including colorectal and breast cancer, non small cell lung cancer, squamous cell carcinoma and melanoma.[@R1]^,^[@R2] This modality, however, has remained inadequately exploited for the treatment of pediatric cancers. Unlike chemotherapy or radiation, MoAb is not myelosuppressive and genotoxic, generally with few long-term toxicities. These are critical considerations for young children. More importantly, MoAb is effective against metastatic cancer in blood, bone marrow and bone, typically found in high risk neuroblastoma (NB). As a class of agents, the pharmacokinetics and toxicities of human or humanized IgG1 antibodies have been extensively studied. In addition, antibodies can carry cytotoxic immune-based payloads, as well as radioisotopes, toxins or enzymes, thereby increasing the options for targeted therapy.

NB is the most common extracranial solid tumor of childhood. In \~50% of cases, curative strategies must tackle both soft tissue mass and metastases in the bone marrow (BM). Dose-intensive chemotherapy improves tumor resectability and post-surgical irradiation reduces the risk of relapse in the primary site to \< 10%.[@R3] However, BM disease, as evidenced by histology or metaiodobenzylguanidine (MIBG) scan, often persists and forebodes a lethal outcome.[@R4]^,^[@R5] In addition, osteomedullary relapse is common, despite achieving near complete remission after induction therapy. Attempts at treatment intensification have met with acute and long-term side effects, both of grave concern for young patients. There is a scarcity of promising new agents, and to date, few if any target/pathway-specific small molecules have shown major clinical benefit in patients with NB, although many promising leads continue to accumulate.[@R6] With a cure rate of \< 30% at toxicity limits among Stage 4 patients diagnosed at ≥ 18 mo of age, there is substantial room for improvement.[@R7]

Ganglioside GD2 is an adhesion molecule abundant on NB. It is an ideal target for MoAb-based therapy in NB. Anti-GD2 MoAb mediates highly efficient antibody-dependent cell-mediated cytotoxicity (ADCC) of NB in the presence of human white cells. It also induces complement mediated cytotoxicity (CMC) of NB cells, which lack decay accelerating factor CD55[@R8] and homologous restriction factor CD59.[@R9] Complement deposition on NB cells enhances ADCC through activation of the iC3b receptor on neutrophils,[@R10]^,^[@R11] available even after dose-intensive or myeloablative chemotherapy plus stem cell transplant, provided colony stimulating factors are given.[@R12] Moreover, the use of intensive chemotherapy, which is standard of care for NB to achieve clinical remission, will result in prolonged lymphopenia and immunosuppression,[@R13] such that patients are less likely to reject murine or chimeric MoAb.[@R14]

At least two antibody families have been tested clinically, i.e., 3F8[@R15] and 14.18.[@R16] Chimeric (ch) 14.18 and 14.G2a were both derived from the variable region of murine MoAb 14.18.[@R17] They demonstrate ADCC and CMC of NB and melanoma cells in vivo.[@R18]^-^[@R21] Based on encouraging clinical responses in Phase I studies, ch14.18 was tested in large Phase II studies as consolidation therapy for Stage 4 NB (German NB90 and NB97 studies). For the 166 patients \> 12 mo at diagnosis, even though event free survival was similar in patients receiving ch14.18 when compared with patients on maintenance chemotherapy, overall survival improved, and the rate of BM relapse was reduced.[@R22] In 2001, the Children's Oncology Group (COG) initiated a randomized Phase III trial to study the efficacy of the combination of ch14.18 with GM-CSF and IL-2 in preventing NB relapse in patients in complete remission after autologous stem cell transplant.[@R23] An interim analysis showed a statistically significant improvement in PFS and OS at 2 y.[@R24]

m3F8, a murine IgG3 MoAb specific for GD2, also induces cell death, and mediates efficient ADCC and CMC against NB in vitro.[@R15] Among patients with chemo-resistant marrow disease despite dose-intensive induction plus an aggressive salvage regimen, 80% achieved BM remission usually after 1 to 2 cycles of 5 days of m3F8 plus GM-CSF immunotherapy.[@R25] Given the activity of m3F8 against chemo-resistant marrow disease, its use was expanded to patients in their first remission with encouraging results.[@R26] These favorable clinical outcomes in children could be improved if 3F8 is given as maintenance therapy over the first 3--5 y of highest recurrence risk. However, human anti-mouse antibody (HAMA) is a limiting factor when the immune system recovers following cessation of chemotherapy. One strategy to reduce HAMA is to chimerize or humanize 3F8, which is the subject of this report.

Results
=======

Amino acid sequences of chimeric-3F8 and humanized-3F8-IgG1/IgG4
----------------------------------------------------------------

The CDRs of the heavy and light chains of m3F8 were grafted onto human IgG1 frameworks based on their homology with human frameworks IGG HV3-33 and IGKV3-15, respectively. The amino acid sequences of chimeric and humanized heavy and light chains are shown in [Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"}, respectively. Additional constructs were made replacing the heavy chain sequences of m3F8 and hu3F8-IgG1 with the human IgG4 framework ([Table 3](#T3){ref-type="table"}), transfected into DG44 cells using the bluescript vectors. Both chimeric and humanized 3F8 were purified using standard protein A affinity chromatography.

###### Amino acid sequences of chimeric 3F8 heavy and light chains with **[CDR regions]{.ul}**

  Ch3F8 heavy chain-gamma1
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  QVQLKESGPGLVAPSQSLSITCTVSGFSVT**[NYGVH]{.ul}**WVRQPPGKGLEWLG**[VIWAGGITNYNSAFMS]{.ul}**RLSISKDNSKSQVFLKMNSLQIDDTAMYYCAS**[RGGHYGYALDY]{.ul}**WGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

  Ch3F8 light chain-kappa
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SIVMTQTPKFLLVSAGDRVTITC**[KASQSVSNDVT]{.ul}**WYQQKAGQSPKLLIY**[SASNRYS]{.ul}**GVPDRFTGSGYGTAFTFTISTVQAEDLAVYFC**[QQDYSS]{.ul}**FGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

###### Amino acid sequences of humanized 3F8 heavy and light chain with **[CDR regions]{.ul}**

  Hu3F8 heavy chain-gamma1
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  QVQLVESGPGVVQPGRSLRISCAVSGFSVT**[NYGVH]{.ul}**WVRQPPGKGLEWLG**[VIWAGGITNYNSAFMS]{.ul}**RLTISKDNSKNTVYLQMNSLRAEDTAMYYCAS**[RGGHYGYALDY]{.ul}**WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

  Hu3F8 light chain-kappa
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  EIVMTQTPATLSVSAGERVTITC**[KASQSVSNDVT]{.ul}**WYQQKPGQAPRLLIY**[SASNRYS]{.ul}**GVPARFSGSGYGTEFTFTISSVQSEDFAVYFC**[QQDYSS]{.ul}**FGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

###### Amino acid sequences of chimeric and humanized 3F8 heavy chain of the IgG4 subclass with **[CDR regions]{.ul}**

  Ch3F8 heavy chain-gamma4
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  QVQLKESGPGLVAPSQSLSITCTVSGFSVT**[NYGVH]{.ul}**WVRQPPGKGLEWLG**[VIWAGGITNYNSAFMS]{.ul}**RLSISKDNSKSQVFLKMNSLQIDDTAMYYCAS**[RGGHYGYALDY]{.ul}**WGQGTSVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

  Hu3F8 heavy chain-gamma4
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  QVQLVESGPGVVQPGRSLRISCAVSGFSVT**[NYGVH]{.ul}**WVRQPPGKGLEWLG**[VIWAGGITNYNSAFMS]{.ul}**RLTISKDNSKNTVYLQMNSLRAEDTAMYYCAS**[RGGHYGYALDY]{.ul}**WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

On SDS gel, chimeric and humanized antibodies migrated as IgG with the appropriate size heavy and light chains; and by HPLC they all eluted as whole IgG with \< 10% aggregate formation (data not shown). By ELISA they all bound to GD2 with similar avidity.

Binding kinetics by surface plasmon resonance (SPR)
---------------------------------------------------

With antigen GD2 coated onto CM5 chips, kinetics of antibody binding (k~on~, k~off~ and KD) were compared by SPR using Biacore T-100. All engineered 3F8, including chimeric and humanized IgG1 and IgG4 had comparable k~off~ as m3F8, and better KD than other anti-GD2 antibody such as 14.G2a ([Fig. 1](#F1){ref-type="fig"}) and ME36.1 ([Table 4](#T4){ref-type="table"}). The slow k~off~ of antibodies also translated into a slower wash-off when antibodies were reacted with GD2-positive tumor cells LAN-1 or M14 and then washed multiple times in wash buffer. With each wash, the remaining antibodies on the cell surface were detected using a secondary FITC-labeled goat anti-mouse antibody and mean fluorescent intensity determined by flow cytometry (data not shown).

![**Figure 1.** Comparative binding kinetics of anti-GD2 antibodies on solid phase GD2 when measured by surface plasmon resonance (Biacore T-100).](onci-1-477-g1){#F1}

###### Binding kinetics of chimeric and humanized 3F8 by surface plasmon resonance

  Antibody     k~on~        k~off~       KD (nM)
  ------------ ------------ ------------ ---------
  ch3F8-IgG1   1.15E + 05   1.45E − 03   13 ± 3
  hu3F8-IgG1   9.19E + 04   1.03E − 03   11 ± 1
  ch3F8-IgG4   9.40E + 04   1.28E − 03   14 ± 2
  hu3F8-IgG4   1.18E + 05   1.76E − 03   15 ± 1
  m3F8         1.74E + 05   8.74E − 04   5 ± 1
  14.G2a       1.50E + 05   1.12E − 02   77 ± 8
  ME36.1       1.21E + 05   2.79E − 03   19 ± 7

Low cross-reactivity with other gangliosides
--------------------------------------------

In cross-reactivity studies, hu3F8-H1L1-IgG1 had similar profile as ch3F8-IgG1 and m3F8 ([Table 5](#T5){ref-type="table"}). There was low level of cross-reactivity with GD1b expressed as percent OD by ELISA relative to the OD on solid phase GD2. There was no cross-reactivity of m3F8, hu3F8 or 14.G2a with human N-CAM,[@R27] either by western blots or by SPR (data not shown).

###### Low cross-reactivity with other gangliosides by ELISA (Mean ± SD)

  Antibody     GM2/GD2   GD1a/GD2      GD1b/GD2      GT1b/GD2   GD3/GD2       GQ1b/GD2
  ------------ --------- ------------- ------------- ---------- ------------- ----------
  ch3F8-IgG1   0%        0.2% ± 0.9%   8.8% ± 0.8%   0%         0.2% ± 0.9%   0%
  hu3F8-IgG1   0%        0%            4.5% ± 0.7%   0%         0%            0%
  ch3F8-IgG4   0%        0%            6.1% ± 2.2%   0%         0%            0%
  hu3F8-IgG4   0%        0%            3.1% ± 1.6%   0%         0%            0%
  m3F8         0%        0%            4.1% ± 1.0%   0%         0%            0%
  14.G2a       0%        0%            0% ± 0.9%     0%         0%            0%

Direct cytotoxicity
-------------------

When these antibodies were added to neuroblastoma cells in vitro, they induced direct cell death and slowed down in vitro cell growth. Upon assayed by WST-8 in a 3-d culture system, m3F8 and hu3F8 had similar potency when their EC~50~s were compared ([Table 6](#T6){ref-type="table"}). In contrast, 14.G2a was \~10-fold weaker in tumor cell killing.

###### Direct cytotoxicity of neuroblastoma cell line LAN-1 in the presence of antibodies

  Direct Cytotoxicity   
  --------------------- -----------
  ch3F8-IgG1            4.5 ± 1.2
  hu3F8-IgG1            5.1 ± 1.2
  ch3F8-IgG4            6.4 ± 1.8
  hu3F8-IgG4            3.1 ± 0.0
  m3F8                  1.9 ± 0.2
  14.G2a                47.1

Antibody potency in ADCC and CMC
--------------------------------

Anti-GD2 antibodies were compared in ADCC assays using PBMC and PMN from volunteers as effectors and LAN-1 cells as targets. ADCC potencies of these antibodies were computed as the ratio (EC~50~ for 3F8)/(EC~50~ for MoAb) ([Table 7](#T7){ref-type="table"}). Relative to m3F8, ch3F8-IgG1 and hu3F8-IgG1 were \~300-fold stronger in PBMC-ADCC, and 18-fold stronger in PMN-ADCC. In addition, the maximal cytotoxicity achieved with both chimeric and humanized 3F8 of IgG1 subclass were substantially and consistently higher than that of m3F8 or 14.G2a, irrespective if it was PBMC-ADCC or PMN-ADCC.

###### Antibody potency relative to m3F8 in ADCC and CMC against neuroblastoma LAN-1

  Antibody     PBMC   PMN   NK-92MI-CD16   NK-92MI-CD32   CMC
  ------------ ------ ----- -------------- -------------- ------
  ch3F8-IgG1   390    18    24             13             0.64
  hu3F8-IgG1   217    19    12             15             0.40
  ch3F8-IgG4   0      1     0              3              0.01
  hu3F8-IgG4   0      4     0              1              0.03
  m3F8         1      1     1              1              1
  14.G2a       0.03   1     4              2              0.12

In order to examine the capability of MoAb in ADCC for individual FcR in the absence of inhibitory FcR, we tested ADCC using NK-92MI cells which do not carry human FcR on their cell surface. Upon transfection with human CD16 and CD32, they could mediate efficient ADCC. When these effector cells were used against LAN-1 targets, ch3F8-IgG1 and hu3F8-IgG1 was more efficient (\> 10-fold) than m3F8 in CD16-ADCC, as well as CD32-ADCC. Hu3F8-IgG4 subclass antibodies had minimal PBMC-ADCC, PMN-ADCC, CD16-ADCC and CD32 activity when compared with m3F8. In human CMC, ch3F8, hu3F8 and 14G.2a were not as efficient as m3F8.

A representative panel of human NB cell lines was tested in cytotoxicity assays (CD16-ADCC, CD32-ADCC and CMC; [Table 8](#T8){ref-type="table"}). Even though most NB cell lines were sensitive, those with low GD2 antigen density (e.g., SKNJC2) were resistant. Overall, hu3F8 was generally much more efficient than m3F8 in cytotoxicity.

###### Antibody potency relative to m3F8 in ADCC and CMC against seven neuroblastoma cell lines

                         LAN1     NMB7     SKNLP    BE(1)N    SKNMM   SKNAS   SKNJC2
  ---------------------- -------- -------- -------- --------- ------- ------- --------
  Antigen density/cell   499348   932191   541522   1080289   98613   33512   16089

  Antibody     ADCC-NK92-CD16                                      
  ------------ ---------------- ------ ------ ------ ------ ------ ------------
  ch3F8-IgG1   33.7             47.6   34.5   47.1   52.7   93.0   no killing
  hu3F8-IgG1   13.9             31.3   11.8   35.7   28.6   30.7   no killing
  ch3F8-IgG4   0.0              0.0    0.0    0.0    0.0    0.0    no killing
  hu3F8-IgG4   0.0              0.0    0.0    0.0    0.0    0.0    no killing
  m3F8         1.0              1.0    1.0    1.0    1.0    1.0    no killing
  14G2a        2.1              1.0    1.0    1.3    0.1    0.0    no killing

               ADCC-NK92-CD32                                       
  ------------ ---------------- ----- -------- ------ ------ ------ ------------
  ch3F8-IgG1   14.6             4.8   393.9    25.9   82.3   13.4   no killing
  hu3F8-IgG1   15.1             7.4   1469.3   61.6   58.3   13.1   no killing
  ch3F8-IgG4   1.0              0.8   3.7      1.0    1.3    0.5    no killing
  hu3F8-IgG4   0.8              0.5   19.8     1.1    1.0    0.0    no killing
  m3F8         1.0              1.0   1.0      1.0    1.0    1.0    no killing
  14G2a        2.2              2.3   66.9     4.0    1.0    0.3    no killing

               CMC                                       
  ------------ ------ ------ ------ ------ ------ ------ ------------
  ch3F8-IgG1   0.74   0.19   0.24   0.15   0.08   0.07   no killing
  hu3F8-IgG1   0.40   0.27   0.59   0.20   0.22   0.11   no killing
  ch3F8-IgG4   0.03   0.00   0.00   0.00   0.00   0.00   no killing
  hu3F8-IgG4   0.01   0.00   0.00   0.00   0.00   0.00   no killing
  m3F8         1.00   1.00   1.00   1.00   1.00   1.00   no killing
  14G2a        0.46   0.05   0.10   0.01   0.01   0.02   no killing

Targeting human neuroblastoma xenografts
----------------------------------------

Hu3F8-IgG1 and hu3F8-IgG4 were radiolabeled with ^131^I. They all had comparable immunoreactivity of \~40--45% (data not shown). Their bio-distributions at 48 h were compared with that of ^131^I-m3F8 in mice bearing sc LAN-1 xenografts. Tumor uptake when measured by %ID/gm was comparable between hu3F8-IgG1 (29.6%) and m3F8 (28.6%), nearly double that of hu3F8-IgG4 ([Table 9](#T9){ref-type="table"}). Tumor to non-tumor ratios was comparable among these four antibodies.

###### Targeting of ^131^I-labeled hu3F8 antibodies to LAN-1 xenografts in Biodistribution studies

  LAN-1       \% ID/gm   Tumor to non-tumor ratio                                                              
  ----------- ---------- -------------------------- ------ ----- ------ ----- ------ ----- ------ ----- ------ -----
  Organ       Mean       SEM                        Mean   SEM   Mean   SEM   Mean   SEM   Mean   SEM   Mean   SEM
  Adrenal     2.5        0.3                        3.1    0.5   2.5    0.5   12     2     11     1     11     2
  Bladder     2.5        0.3                        3.1    0.4   1.9    0.3   11     1     10     1     10     1
  Blood       4.2        0.6                        4.4    0.7   3.7    0.6   8      1     7      1     7      1
  Brain       0.2        0.0                        0.2    0.0   0.1    0.0   187    19    132    10    125    10
  Femur       0.8        0.1                        1.2    0.1   0.7    0.1   35     4     24     2     27     3
  Heart       1.7        0.2                        2.2    0.3   1.6    0.2   18     2     13     1     12     1
  Kidney      1.8        0.2                        2.3    0.3   1.6    0.2   16     2     13     1     10     1
  Large Int   1.0        0.1                        1.6    0.2   0.8    0.1   29     4     18     2     22     3
  Liver       2.2        0.2                        3.0    0.4   1.7    0.3   13     1     10     1     10     1
  Lung        2.9        0.4                        3.5    0.5   2.4    0.3   11     1     8      1     7      1
  Muscle      0.6        0.1                        0.9    0.1   0.5    0.1   44     4     33     3     33     3
  Skin        2.1        0.3                        4.0    0.6   1.9    0.3   14     2     8      1     9      1
  Small Int   0.7        0.1                        1.1    0.1   0.5    0.1   39     4     26     3     30     3
  Spine       1.0        0.1                        1.4    0.2   0.9    0.1   27     2     21     2     21     2
  Spleen      4.2        0.6                        3.9    0.5   1.3    0.1   9      1     8      1     12     1
  Stomach     1.5        0.2                        2.4    0.2   1.4    0.2   21     2     12     1     13     2
  Tumor       28.6       4.2                        29.6   3.8   16.0   1.9   1      0     1      0     1      0

Treatment of neuroblastoma xenografts using 3F8 antibodies
----------------------------------------------------------

LAN-1 is one of the most widely studied human NB cell lines. Even though the mouse effectors and mouse complement were generally suboptimal for testing monoclonal antibodies, it is the only established model for in vivo assays.[@R28] Mice xenografted with established human NB LAN-1 (0.5--1 cm diameter) were treated with iv m3F8 or hu3F8-IgG1 twice weekly for 4 weeks. Tumor size, weight, and survival were monitored. Hu3F8-IgG1 (100 µg dose) inhibited tumor growth significantly (p \< 0.05), when compared with m3F8 (200 µg dose) or control mIgG3 (100 µg dose). At 20 µg dose, hu3F8-IgG1 was not effective ([Fig. 2](#F2){ref-type="fig"}). Hu3F8-IgG1 (200 µg dose) was not more effective than hu3F8-IgG1 (100 µg dose) (data not shown). Survival of mice receiving 100--200 µg were significantly longer (p = 0.003) than mice receiving PBS control or m3F8 (data not shown).

![**Figure 2.** Treatment of LAN-1 subcutaneous neuroblastoma xenografts in athymic nude mice. Antibodies were administered intravenously twice weekly for a total of 8 doses. m3F8 and control mouse IgG3 had no effect on tumor growth. 100--200 ug of hu3F8-IgG1 had the strongest anti-tumor effect (p \< 0.05, student t-test after day 21 of treatment), whereas such effect was substantially less if 20 ug was used.](onci-1-477-g2){#F2}

Discussion
==========

Anti-GD2 antibody is a proven therapy for GD2-postive NB.[@R29] Murine antibody 14.18 and its derivatives (14.G2a and ch14.18) have provided benchmarks for improving anti-GD2 therapy. We chose murine IgG3 antibody m3F8 for clinical development because of its 10-fold slower k~off~, when compared with 14.G2a in GD2 binding kinetics by SPR. Among patients with chemo-resistant metastatic NB in the bone marrow, m3F8 plus GM-CSF induced 80% complete remissions,[@R30] and among patients with high risk metastatic NB in first remission, m3F8 plus GM-CSF was associated with \> 75% overall long-term survival.[@R26] However, HAMA can diminish the effect of the murine antibody by neutralizing its ability to bind to its antigen, by blocking the direct effect of the antibody, and by accelerating the clearance of the antibody from circulation. Genetic engineering to change murine to human IgG frameworks should reduce the HAMA response. Ch14.18[@R31]^,^[@R32] and hu14.18[@R33] (both derived from the VH and VL of 14.G2a) have reduced immunogenicity in some but not all patients. We therefore tested the chimeric and humanized forms of 3F8 as potential next generation anti-GD2 antibodies

One criterion for successful chimerization and humanization is the preservation of affinity during genetic engineering. It was reassuring that a slow k~off~ in ch3F8 and hu3F8 was maintained. But more importantly, the preservation and enhancement of in vitro effector function, as well as in vivo tumor targeting plus in vivo therapeutic properties could be critical. Both ch3F8-IgG1 and hu3F8-IgG1 showed \> 200 fold more efficient PBMC-ADCC than m3F8, while PMN-ADCC was 19-fold. In sharp contrast, for CMC, ch3F8 and hu3F8 had substantially lower complement activating ability than m3F8.

This huge improvement in ADCC is most desirable, given recent evidence for its role in the anti-tumor effects of MoAb in patients. Among lymphoma patients treated with rituximab, both high affinity FcR2A and FcR3A were shown to have better response and survival advantage.[@R34] While the high affinity receptor FcR3A translated into \< 10 improvement in ADCC in vitro,[@R35] overall response and time to progression improved by 200%.[@R34] When metastatic breast cancer was treated with Herceptin, patients with high affinity FcR3A had better overall response (83% vs. 35%, p = 0.03), and longer progression-free survival (p = 0.005).[@R36] For metastatic colorectal cancer treated with cetuximab, patients with low affinity FcR2A and FcR3A had comparable hazard ratios as patients with mutated *KRAS*.[@R37] Using m3F8, patients with the high affinity FcR3A receptor on myeloid cells were shown to have better survival.[@R38]

While binding affinity and effector functions are critical for therapeutic applications, cross-reactivity can pose unexpected toxicity issues. We showed that these chimeric and humanized forms for 3F8 had comparable cross-reactivity patterns as m3F8 both by ELISA assays with purified gangliosides, as well as by immunohistochemistry on a panel of normal human tissues (data not shown). Similar to m3F8, these engineered antibodies showed low level of reactivity to GD1b when compared with GD2. GD1b has been shown to be a highly prevalent ganglioside among NB tumors, especially when differentiated by retinoids.[@R39]^,^[@R40] This may be relevant, since 13-cis-retinoic acid is routinely given to patients undergoing immunotherapy for high risk NB. However, anti-GD1b antibodies have also been associated with sensory ataxic neuropathies.[@R41] Nevertheless, the safety profile of m3F8 with no permanent or late sensory neuropathies in more than 500 patients is reassuring.

CMC is unusually effective against human NB[@R42] because of its low expression of CD55[@R8] and CD59.[@R9] All anti-GD2 antibodies mediate efficient CMC, and m3F8 seems particularly effective. Yet, several studies with rituximab have suggested a negative role of complement activation in downregulating ADCC.[@R43] In clinical studies, higher activity of complement component C1qA was associated with less favorable response to rituximab therapy.[@R44] For anti-GD2 antibodies, complement activation was thought to be responsible for the pain side effects;[@R45] hence the Fc-CH2 domain mutated version (hu14.18K322A) is currently in clinical trial. Given these considerations, an overdrive of CMC is probably not desirable. It is reassuring that the increase in ADCC efficiency of both ch3F8 and hu3F8 were not accompanied by increased CMC.

In summary hu3F8 retains a slow k~off~, allowing them to remain on tumor cell surface for longer periods. It mediates more potent ADCC in vitro and anti-tumor activity in vivo, while maintaining excellent targeting efficiency when compared with m3F8. By leveraging ADCC over CMC, hu3F8 treatment could potentially be made less painful, with reduced incidence or even avoidance of neutralizing antibodies. Preliminary results of the Phase I clinical trial of hu3F8 (Clinicaltrials.gov NCT01419834) have confirmed the low immunogenicity of hu3F8, with highly favorable pharmacokinetics.

Materials and Methods
=====================

Cell culture and human tissues
------------------------------

Human NB cell line LAN-1 was provided by Dr Robert Seeger (Children's Hospital of Los Angeles), and NB1691 by Dr Peter Houghton (St. Jude Children\'s Research Hospital). NK-92MI was obtained from American Type Culture Collection (ATCC). All cell lines were grown in F10 \[RPMI 1640 medium supplemented with 10% fetal bovine serum (Hyclone, South Logan, UT), 2 mM glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C in a 5% CO~2~ incubator. Normal tissues as well as solid tumor samples of different histological types obtained at Memorial Sloan-Kettering Cancer Center (MSKCC) were snap-frozen in liquid nitrogen.

Monoclonal antibodies
---------------------

m3F8 was a mouse IgG3 antibody with kappa light chain,[@R15] its anti-NB activity has been previously described.[@R15]^,^[@R46]^,^[@R47] It was produced as ascites and purified by affinity chromatography: protein A (GE Healthcare) with \> 90% pure by SDS-PAGE. Anti-GD2 hybridoma ME36.1 was obtained from ATCC. 14.G2a was purchased from BD Biosciences.

Construction of the hu3F8-IgG1, hu3F8-IgG4, ch3F8-IgG1, and ch3F8-IgG4 antibody producer lines
----------------------------------------------------------------------------------------------

Based on human homologs of m3F8, CDR sequences of both heavy and light chains of m3F8 were grafted into the human IgG1 framework and optimized. These hu3F8 genes were synthesized for CHO cells (Blue Heron Biotechnology or Genscript). Using the bluescript vector (Eureka, CA), these heavy and light chain genes of hu3F8 were transfected into DG44 cells and selected with G418 (InVitrogen, CA). Similarly, mouse VH and VL sequences were grafted onto human IgG1 and IgG4 frameworks to make the ch3F8-IgG1 and ch3F8-IgG4 recombinant antibodies. From two heavy chain and two light chain designs, four versions of hu3F8 genes were synthesized and expressed in DG44 cells. Based on in vitro stability, binding kinetics to GD2 by Biacore, and efficiency in ADCC, the final heavy and light chain sequences of hu3F8-IgG1 were chosen.

Purification of Hu3F8 and ch3F8
-------------------------------

Hu3F8 and ch3F8 producer lines were cultured in Opticho serum free medium (InVitrogen) and the mature supernatant harvested. Protein A affinity column was pre-equilibrated with 25 mM sodium citrate buffer with 0.15 M NaCl, pH 8.2. Bound hu3F8 was eluted with 0.1 M citric acid/sodium citrate buffer, pH 3.9 and alkalinized (1:10 v/v ratio) in 25 mM sodium citrate, pH 8.5. It was passed through a Sartobind-Q membrane and concentrated to 5--10 mg/ml in 25 mM sodium citrate, 0.15 M NaCl, pH 8.2. Stability studies were performed on hu3F8-IgG1 in 25 mM sodium citrate 0.15 M NaCl pH 8.2 vs. PBS pH 7.4 in the presence or absence of 0.7 mg/ml of Tween 80 (Sigma). Two micrograms each of the proteins was analyzed by SDS-PAGE under non-reducing or reducing conditions using 4--15% Tris-Glycine Ready Gel System (Bio-Rad). Invitrogen SeeBlue Plus2 Pre-Stained Standard was used as the protein molecular weight marker. After electrophoresis, the gel was stained using PIERCE's GelCode Blue Stain Reagent. The gel was scanned using Bio-Rad Fluor-S MultiImager (Bio-Rad), and the band intensity quantified with Quantity One software (Bio-Rad).

Quantitation of hu3F8 and ch3F8 by ELISA
----------------------------------------

Microtiter plates were coated with GD2 at 20 ng per well. 150 µl per well of 0.5% BSA in PBS (diluent) was added to each plate for at least 30 min at ambient temperature to block excess binding sites. A purified batch of hu3F8-IgG1 was used to construct a standard curve starting at 0.5 µg/ml followed by 2-fold dilutions. 100 µl of standard and samples (also diluted 2-fold) were added to each well and incubated for 2.5 h at 37°C. After washing the plates with PBS, 100 µl of goat anti human-IgG (H^+^L) (Jackson Research Laboratory) diluted at 1:3500 in diluent was added to each well and incubated for 1 h at 4°C. ELISA color reaction was developed with chromogen OPD (Sigma) with the substrate hydrogen peroxide for 30 min at room temperature (RT) in the dark. The reaction was stopped with 5N H~2~S0~4~ and the optical density (OD) read with ELISA plate reader MRX (Dynex) at 490 nm. Based on the standard curve, quantitation of hu3F8 and ch3F8 supernatants was calculated in micrograms/milliliters or micrograms/milligrams of protein.

In vitro binding kinetics by Biacore T-100 Biosensor (Biacore AB of GE Healthcare)
----------------------------------------------------------------------------------

CM5 sensor chip (Research grade) and related reagents were purchased from Biacore USA. The gangliosides GM1 was from ALEXIS Biochemicals (AXXORA L.L.C.), and GD2 from Advanced ImmunoChemical. In brief, gangliosides were directly immobilized onto the CM5 sensor chip via hydrophobic interaction.[@R48]^,^[@R49] Reference surface was immobilized with GM1. Active surface was immobilized with GD2 and GM1 in 1:1 ratio. Diluted mixture of GD2 and GM1 (50 μg/ml) was injected (300 μl) at a flow rate of 15 μl/min over 20 min. Extensive washing was followed with 10 mM NaOH (typically five washes of 20 μl at a flow rate of 5 μl /min) until a stable baseline was obtained.

Purified anti-GD2 MoAb were diluted in HBS-E buffer containing 250 mM NaCl at varying concentrations (50 \~1600 nM) prior to analysis. Samples (60 μl) were injected over the sensor surface at a flow rate of 30 μl/min over 2 min. Following completion of the association phase, dissociation was monitored in HBS-E buffer containing 250 mM NaCl for 300 sec at the same flow rate. At the end of each cycle, the surface was regenerated using 50 μl 20 mM NaOH at a flow rate of 50 μl/min over 1 min and 100 μl 4M MgCl~2~ at a flow rate of 50 μl/min over 2 min. The biosensor curves obtained following injection of the samples over immobilized GD2 were subtracted with the control curves obtained with the samples injected over immobilized GM1 prior to kinetics analysis. The data were analyzed by the bivalent analyte model and default parameter setting for the rate constants using the Biacore T-100 evaluation software, and the apparent association on rate constant (k~on~), dissociation off rate constant (k~off~) and equilibrium dissociation constant (KD = k~off~/k~on~) were calculated.

ELISA for cross-reactivity with other gangliosides
--------------------------------------------------

GD2, GM2, GD1a, GD1b, GT1b, GD3, as well as GQ1b were coated on polyvinyl microtiter plates at 20 ng per well in 90% ethanol. Following air drying, wells were blocked with 0.5% BSA in PBS at 150 μl per well for 1 h at room temperature. Antibodies were added in triplicates at 1 μg/ml (100 μl per well) in 0.5% BSA. For background subtraction, wells with (1) no antigen and (2) no sample were used. Following incubation for 2 h at 37°C and washing with PBS, HRP-goat anti-mouse IgG at 1:1000 dilution for mouse antibodies or HRP-goat anti-human IgG at 1:1000 dilution for humanized antibodies, all from Jackson Research Laboratory, were added. After incubation for 1 h at 4°C and further washing, color reaction was performed and OD was read using ELISA plate reader at 490 nm, and cross-reactivity expressed as % maximal binding to GD2.

Direct cytotoxicity
-------------------

Antibodies were tested for their direct effect on tumor cell growth and survival in the absence of human serum or human effector cells. Tumor targets were dissociated with 2mM EDTA or Trypsin-EDTA, washed and plated onto 96-well flat bottom plates in F10 at 1.2 × 10^3^ to 3.5 × 10^4^ per well. After incubation for 24 h in a 5% CO~2~ incubator at 37°C, increasing concentrations of antibodies in F10 are added to each well. Control wells received F10 alone. After incubation for 72 h at 37°C in 5% CO~2~, WST-8 reagent (Cayman Chemical Co.). was added to each well and incubated in the dark in a CO~2~ incubator at 37°C for 2--6 h. OD was read at 450 nm and 690 nm using ELISA plate reader. WST-8 assay was validated using direct cell counting using Trypan Blue (Sigma) or Beckman Coulter Counter (Beckman Coulter).

Antibody-dependent cell-mediated cytotoxicity (ADCC) by ^51^Chromium Release
----------------------------------------------------------------------------

Target cells were detached with 2 mM EDTA in Ca2^+^ Mg2^+^ free PBS and washed in F10. Antigen density was estimated using Quantum Simply Cellular anti-Mouse IgG beads according the manufacturer's instructions (Bangs Laboratories, Inc.). For cytotoxicity assays, 100 μCi of ^51^Cr was incubated with 10^6^ target cells in a final volume of 250 μl and incubated for 1 h at 37°C with gentle resuspension of pellet at 15 min intervals. Cells were then washed and resuspended in 250 µl F10 and incubated for 30 min at 37°C. After washing, cells were counted and viability determined with Trypan Blue and quickly plated onto 96 well U-bottom plates. Peripheral blood from normal volunteers was collected into heparinized tubes. Blood was mixed with 3% dextran/PBS and kept at room temperature for 20 min to sediment the red cells. White cells were then ficolled and separated into peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN) for PBMC-ADCC and PMN-ADCC, respectively. Cells were washed in F10, counted and viability determined. PBMC-ADCC was done in the presence of 10 U/ml of IL-2 and PMN-ADCC in 2 ng/ml of GM-CSF. Antibodies were diluted in F10 from 1 µg/ml in 10-fold dilutions. Plates were incubated in a 37°C, 5% CO~2~ incubator for 4 h. Released ^51^Cr in the ADCC supernatant was collected for gamma counting. Total release was determined using 10% sodium dodecyl sulfate (SDS) and background spontaneous release was determined with F10 only without effectors. An effector:target (E:T) ratio of 50:1 was generally used. Similarly, ADCC assays were performed using NK-92MI cells stably transfected with the human CD16 or human CD32 Fc receptors. Unlike PBMC or PMN, no cytokines were needed in the assay. E:T ratio was generally kept at 20:1.

Biodistribution of MoAb in xenografted mice
-------------------------------------------

Female athymic nude mice were purchased from Harlan Spraque Dawley, Inc. All procedures were performed in accordance with the protocols approved by our Institutional Animal Care and Use Committee and institutional guidelines for the proper and humane use of animals in research. LAN-1 tumor cells were harvested and resuspended in Matrigel (BD Biosciences). Cells (2 \~10 × 10^6^) were implanted subcutaneously (sc) to the flank of the mice in 0.1 ml volume using 22-gauge needles. Tumors were allowed to grow to the size of \~200 mm^3^ before initiating treatment. Mice with established tumors were randomly separated into treatment groups. 100 µCi of radioiodinated antibody per mouse was injected intravenously and animals sacrificed usually at 48 h, and their organs removed and counted in a gamma counter (Packard Instruments, Perkin Elmer). These organs included skin, liver, spleen, kidney, adrenal, stomach, small intestine, large intestine, bladder, femur, muscle, tumor, heart, lung, spine, and brain. Based on the µCi accumulated in the organ and the organ weight, % injected dose (ID)/gm of mouse was calculated. Tumor to non-tumor ratios of % ID/gm was also calculated.

Therapy of LAN-1 neuroblastoma xenografts
-----------------------------------------

Studies commenced when sc tumors reached \~200 mg. Mice were randomly assigned to treatment groups (n = 5). Antibodies were administered intravenously (iv) twice a week for a total of eight doses. Tumor volume and body weight were measured twice per week. Differences between tumor sizes were tested for significance by Student\'s t-test.

Hu3F8 patent was filed by Memorial Sloan-Kettering Cancer Center, and N.-K.C. was named as the inventor.
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